Composition for contraception

Abstract

A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17β-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.302.5 to 3.0 mg of drospirenone and 0.1 to 0.21 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.

We claim:  
     
       1. A combination product for oral contraception, comprising 
       (a) 23 or 24 dosage units, each containing an estrogen selected from  
       >2.0 to 6.0 mg of 17β-estradiol and  
       0.020 mg of ethinylestradiol;  
       and a gestagen selected from 
       0.25 to  0.30  2.5 to 3.0  mg of drospirenone and  
       0.1 to  0.2  1 to 2  mg of cyproterone acetate,  
       and 
       b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days.  
     
     
       2. A combination preparation for oral contraception according to  claim 1 , wherein the estrogen is ethinylestradiol. 
     
     
       3. A combination preparation of  claim 2 , wherein the gestagen is cyproterone acetate. 
     
     
       4. A combination preparation of  claim 2 , wherein the gestagen is drospirenone. 
     
     
       5. A combination preparation according to  claim 1 , wherein the estrogen is present in a dose of 20 μg of ethinylestradiol or an equivalent dose of 17β-estradiol and the gestagen is present in a dose equivalent to 75 μg of gestadene. 
     
     
       6. A combination preparation according to  claim 1 , which comprises 23 dosage units and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle. 
     
     
       7. A combination preparation according to  claim 1 , which comprises 23 dosage units, each containing 20 μg of ethinylestradiol and a dose of cyproterone acetate or drospirenone equivalent to 75 μg of gestodene and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle. 
     
     
       8. A combination preparation of  claim 1 , wherein the estrogen is 17β-estradiol. 
     
     
       9. A combination preparation of  claim 8 , wherein the gestagen is cyproterone acetate. 
     
     
       10. A combination preparation of  claim 8 , wherein the gestagen is drospirenone. 
     
     
       11. A combination preparation of  claim 4 , which comprises  23  dosage units and  5  placebo pills or other indications to show that no dosage unit or placebo pill is administered during the last  5  days of the menstrual cycle. 
     
     
       12. A combination preparation of  claim 4 , which comprises  24  dosage units and  4  placebo pills or other indications to show that no dosage unit or placebo pill is administered during the last  4  days of the menstrual cycle. 
     
     
       13. A combination product for oral contraception, comprising 
       ( a )    23  or  24  daily dosage units, each containing    
       
           0 . 020  mg of ethinylestradiol, and  
       
       
           2 . 5  to  3 . 0  mg of drospirenone,  
       
         and    
       ( b )    5  or  4 , respectively, active ingredient - free placebo pills or other indications to show that the daily administration of the  23  or  24  dosage units, respectively, is to be followed by  5  or  4 , respectively, pill - free or placebo pill days,    
       
         wherein each of the dosage units containing drospirenone contains the same amount of drospirenone. 
       
     
     
       14. A combination preparation of  claim 13 , which comprises  23  dosage units and  5  placebo pills or other indications to show that no dosage unit or placebo pill is administered during the last  5  days of the menstrual cycle. 
     
     
       15. A combination preparation of  claim 13 , which comprises  24  dosage units and  4  placebo pills or other indications to show that no dosage unit or placebo pill is administered during the last  4  days of the menstrual cycle.